Cargando…
Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity
Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction. Accurately detecting heterogeneity for the development of biomarkers and the detection of the clones resistant to therapy is one of the main goals of contemporary medicine. Metastases belong to the natural history...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643448/ https://www.ncbi.nlm.nih.gov/pubmed/31367241 http://dx.doi.org/10.7150/thno.34337 |
_version_ | 1783437125119639552 |
---|---|
author | Tellez-Gabriel, Marta Heymann, Marie-Françoise Heymann, Dominique |
author_facet | Tellez-Gabriel, Marta Heymann, Marie-Françoise Heymann, Dominique |
author_sort | Tellez-Gabriel, Marta |
collection | PubMed |
description | Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction. Accurately detecting heterogeneity for the development of biomarkers and the detection of the clones resistant to therapy is one of the main goals of contemporary medicine. Metastases belong to the natural history of cancer. The present review gives an overview on the origin of tumor heterogeneity. Recent progress has made it possible to isolate and characterize circulating tumor cells (CTCs), which are the drivers of the disease between the primary sites and metastatic foci. The most recent methods for characterizing CTCs are summarized and we discuss the power of CTC profiling for analyzing tumor heterogeneity in early and advanced diseases. |
format | Online Article Text |
id | pubmed-6643448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-66434482019-07-31 Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity Tellez-Gabriel, Marta Heymann, Marie-Françoise Heymann, Dominique Theranostics Review Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction. Accurately detecting heterogeneity for the development of biomarkers and the detection of the clones resistant to therapy is one of the main goals of contemporary medicine. Metastases belong to the natural history of cancer. The present review gives an overview on the origin of tumor heterogeneity. Recent progress has made it possible to isolate and characterize circulating tumor cells (CTCs), which are the drivers of the disease between the primary sites and metastatic foci. The most recent methods for characterizing CTCs are summarized and we discuss the power of CTC profiling for analyzing tumor heterogeneity in early and advanced diseases. Ivyspring International Publisher 2019-06-19 /pmc/articles/PMC6643448/ /pubmed/31367241 http://dx.doi.org/10.7150/thno.34337 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Tellez-Gabriel, Marta Heymann, Marie-Françoise Heymann, Dominique Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity |
title | Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity |
title_full | Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity |
title_fullStr | Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity |
title_full_unstemmed | Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity |
title_short | Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity |
title_sort | circulating tumor cells as a tool for assessing tumor heterogeneity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643448/ https://www.ncbi.nlm.nih.gov/pubmed/31367241 http://dx.doi.org/10.7150/thno.34337 |
work_keys_str_mv | AT tellezgabrielmarta circulatingtumorcellsasatoolforassessingtumorheterogeneity AT heymannmariefrancoise circulatingtumorcellsasatoolforassessingtumorheterogeneity AT heymanndominique circulatingtumorcellsasatoolforassessingtumorheterogeneity |